Recombinant Human CD137 / 4-1BB / TNFRSF9 Protein (Catalog#10041-H08H)
This antibody was obtained from a rabbit immunized with purified, recombinant Human CD137 / 4-1BB / TNFRSF9 (rh CD137 / 4-1BB / TNFRSF9; Catalog#10041-H08H; NP_001552.2; Met1-Gln186) and conjugated with APC under optimum conditions, the unreacted APC was removed.
Monoclonal Rabbit IgG Clone #819
Aqueous solution containing 0.5% BSA and 0.03%ProClin300
10 μl/Test, 0.1 mg/ml
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze !
Flow cytometric analysis of Human CD137 expression on human whole blood lymphocytes. Cells were stained with APC-conjugated anti-Human CD137. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor necrosis factor receptor–associated factors (TRAFs), the adaptor protein which mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T-cell activation and growth, as well as monocyte proliferation and B-cell survival, and plays an important role in the amplification of T cell-mediated immune responses. In addition, CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors. Crosslinking of CD137 on activated T cells has shown promise in enhancing anti-tumor immune responses in murine models, and agonistic anti-CD137 antibodies are currently being tested in phase I clinical trials. Soluble forms of CD137 (sCD137) are generated by differential splicing. sCD137 can bind to CD137 ligand to antagonize the costimulatory activities of the membrane-bound CD137 and reduce T cell proliferation and IL-2 secretion.